Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group

被引：19

作者：

Comella, Pasquale ^{[1
]}

Lorusso, Vito ^{[2
,7
]}

Maiorino, Luigi ^{[3
]}

Casaretti, Rossana ^{[1
]}

Cannone, Michele ^{[4
]}

Massidda, Bruno ^{[5
]}

Putzu, Carlo ^{[6
]}

Leo, Silvana ^{[7
]}

Roselli, Mario ^{[8
]}

Mancarella, Sergio ^{[9
]}

Palmeri, Sergio ^{[10
]}

Greco, Ettore ^{[11
]}

Vessia, Giacomo ^{[12
]}

Sandomenico, Claudia ^{[1
]}

Franco, Luca ^{[1
]}

机构：

[1] Natl Tumour Inst, Dept Gastrointestinal Tumours, Med Oncol Unit, I-80131 Naples, Italy

[2] Inst Oncol, Med Oncol Unit, Bari, Italy

[3] San Gennaro Hosp, Med Oncol Unit, Naples, Italy

[4] City Hosp, Med Oncol Unit, Canosa, Italy

[5] Univ Cagliari, Chair Med Oncol, Cagliari, Italy

[6] Univ Sassari, Chair Med Oncol, I-07100 Sassari, Italy

[7] City Hosp, Med Oncol Unit, Lecce, Italy

[8] Univ Roma Tor Vergata, Chair Med Oncol, Rome, Italy

[9] City Hosp, Med Oncol Unit, Galatina, Italy

[10] Univ Palermo, Chair Med Oncol, Palermo, Italy

[11] City Hosp, Med Oncol Unit, Lametia Terme, Italy

[12] City Hosp, Med Oncol Unit, Altamura, Italy

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2009年 / 64卷 / 05期

关键词：

Gastric cancer; Fluorouracil; Irinotecan; Oxaliplatin; Triplet regimen; ADVANCED ESOPHAGOGASTRIC CANCER; METASTATIC COLORECTAL-CANCER; FOLINIC ACID; 1ST-LINE TREATMENT; PLUS OXALIPLATIN; INFUSIONAL; 5-FLUOROURACIL; BIWEEKLY OXALIPLATIN; REGIMEN EVERY; CISPLATIN; CHEMOTHERAPY;

D O I：

10.1007/s00280-009-0938-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

This phase II trial assessed the tolerability and efficacy of a triplet of oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer. Patients with unresectable or metastatic gastric cancer, unexposed to palliative chemotherapy, received oxaliplatin 85 mg/m(2) iv and irinotecan 150 mg/m(2) iv on day 1, 6S-folinic acid 250 mg/m(2) iv and fluorouracil 750 mg/m(2) iv on day 2, every 2 weeks. Response rate (RR) was assessed after a minimum of four cycles, and treatment continued up to 12 cycles. Sixty-three patients were treated, with a median of eight (range 1-12) cycles/patient. Two complete and 19 partial responses were registered (RR 33% [95% CI, 22-46%]). Median progression-free survival was 7.5 (95% CI, 5.6-9.4) months, and median overall survival was 12.1 (95% CI, 10.8-13.4) months. Most common grade a parts per thousand yen3 toxicities were neutropenia (59%), febrile neutropenia (7%), vomiting (20%), and diarrhoea (10%). All-grade neurotoxicity affected 33% of patients. Oxaliplatin, irinotecan, and fluorouracil/folinic acid administered every 2 weeks are safe and active in advanced gastric cancer.

引用

页码：893 / 899

页数：7

共 39 条

[1]

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin:: A study of the arbeitsgemeinschaft internistische onkologie [J].

Al-Batran, Salah-Eddin ;

Hartmann, Joerg Thomas ;

Probst, Stephan ;

Schmalenberg, Harald ;

Hollerbach, Stephan ;

Hofheinz, Ralf ;

Rethwisch, Volker ;

Seipelt, Gernot ;

Homann, Nils ;

Wilhelm, Gerhard ;

Schuch, Gunter ;

Stoehlmacher, Jan ;

Derigs, Hans Guenter ;

Hegewisch-Becker, Susanna ;

Grossmann, Johannes ;

Pauligk, Claudia ;

Atmaca, Akin ;

Bokemeyer, Carsten ;

Knuth, Alexander ;

Jaeger, Elke .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) :1435-1442

[2]

Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer [J].

Al-Batran, SE ;

Atmaca, A ;

Hegewisch-Becker, S ;

Jaeger, D ;

Hahnfeld, S ;

Rummel, MJ ;

Seipelt, G ;

Rost, A ;

Knuth, JOA ;

Jaeger, E .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (04) :658-663

[3]

Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma [J].

Assersohn, L ;

Brown, G ;

Cunningham, D ;

Ward, C ;

Oates, J ;

Waters, JS ;

Hill, ME ;

Norman, AR .

ANNALS OF ONCOLOGY, 2004, 15 (01) :64-69

[4]

Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer [J].

Bajetta, E. ;

Celio, L. ;

Ferrario, E. ;

Di Bartolomeo, M. ;

Denaro, A. ;

Dotti, K. ;

Mancin, M. ;

Bajetta, R. ;

Colombo, A. ;

Pusceddu, S. .

ANNALS OF ONCOLOGY, 2007, 18 (11) :1810-1816

[5]

Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic,gastric cancer:: A Federation Francophone de Cancerologie Digestive Group Study -: FFCD 9803 [J].

Bouche, O ;

Raoul, JL ;

Bonnetain, F ;

Giovannini, M ;

Etienne, PL ;

Lledo, G ;

Arsène, D ;

Paitel, JF ;

Guérin-Meyer, V ;

Mitry, E ;

Buecher, B ;

Kaminsky, MC ;

Seitz, JF ;

Rougier, P ;

Bedenne, L ;

Milan, C .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (21) :4319-4328

[6]

Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer [J].

Chao, Y ;

Yeh, KH ;

Chang, CJ ;

Chen, LT ;

Chao, TY ;

Wu, MF ;

Chang, CS ;

Chang, JY ;

Chung, CY ;

Kao, WY ;

Hsieh, RK ;

Cheng, AL .

BRITISH JOURNAL OF CANCER, 2004, 91 (03) :453-458

[7]

Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data [J].

Chou, I ;

Norman, AR ;

Cunningham, D ;

Waters, JS ;

Oates, J ;

Ross, PJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2395-2403

[8]

Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies [J].

Comella, P ;

Casaretti, R ;

De Rosa, V ;

Avallone, A ;

Izzo, F ;

Fiore, F ;

Lapenta, L ;

Comella, G .

ANNALS OF ONCOLOGY, 2002, 13 (12) :1874-1881

[9]

Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer [J].

Comella, Pasquale ;

Massidda, Bruno ;

Palmeri, Sergio ;

Putzu, Carlo ;

De Rosa, Vincenzo ;

Izzo, Francesco ;

Fiore, Francesco ;

Casaretti, Rossana ;

Sandomenico, Claudia .

ANTI-CANCER DRUGS, 2006, 17 (08) :985-992

[10]

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer [J].

Cunningham, D ;

Jost, LM ;

Purkalne, G ;

Oliveira, J .

ANNALS OF ONCOLOGY, 2005, 16 :22-23

← 1 2 3 4 →